L.D. Van de Kar

Amygdaloid lesions : differential effect on conditioned stress and immobilization-induced increases in corticosterone and renin secretion

The purpose of this study was to examine the contribution of the central nucleus of the amygdala to the expression of stress-induced increase in corticosterone and renin secretion. Neurons in the central amygdaloid nucleus of male rats were destroyed by bilateral injections of ibotenic acid, a neurotoxin that destroys cells but leaves fibers of passage intact. Two weeks later, the rats were subjected to immobilization for 20 min or to a conditioned stress (conditioned emotional response) procedure. Central amygdala lesions inhibited the increases in plasma corticosterone after exposure to both conditioned stress and immobilization. Lesions in the lateral amygdala had no effect on the corticosterone response to either stressor. Lesions in the central amygdala attenuated the renin response to conditioned stress but not to immobilization. In contrast, lateral amygdala lesions potentiated the renin response to immobilization but did not affect the renin response to conditioned stress. The results confirm previous studies that demonstrate the importance of the central amygdaloid nucleus in the expression of corticosterone to immobilization stress. In addition, the results show that neurons within the central amygdaloid nucleus are necessary for the full expression of conditioned stress-induced increase in corticosterone and renin secretion. The results are discussed with respect to the potential pathways that mediate stress-induced increases in corticosterone and renin secretion.

Cerebrospinal fluid oxytocin, life history of aggression, and personality disorder

BACKGROUND Data from animal studies have identified oxytocin as an important modulator of social aggression. We have previously reported on a relationship between cerebrospinal fluid (CSF) levels of vasopressin and life history of aggressive behavior, a finding that is consistent with animal data. We hypothesized that CSF Oxytocin levels would be inversely related to dimensional measures of lifetime aggression. METHODS Lumbar CSF for morning basal levels of oxytocin was obtained from 58 consenting subjects with and without DSM-IV personality disorders. Aggression was assessed dimensionally using an interview instrument (Life History of Aggression (LHA)). The primary analysis was conducted using a linear regression model predicting variance in CSF Oxytocin concentration, including the predictors of LHA score, Sex, Height, and the presence or absence of personality disorder. RESULTS The model predicting variance in CSF Oxytocin concentration including LHA score was statistically significant, after removal of a single multivariate outlier. Inclusion of the outlier resulted in a most likely spurious interaction between Sex and LHA score. Presence or absence of personality disorder was not associated with variance in CSF Oxytocin levels. Exploratory analyses revealed a possible inverse relationship between CSF Oxytocin level and history of suicidal behavior. CONCLUSIONS As hypothesized, CSF Oxytocin levels were inversely correlated with life history of aggression. This represents the first such report of a relationship between oxytocin levels and aggression. The correlational, cross-sectional study design precludes causal inferences, but the data are consistent with the known effects of oxytocin on aggressive behavior in animals.

Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion

The present study was undertaken to determine the involvement of serotonergic 5-HT1 and 5-HT2 receptor subtypes in stimulation of the secretion of prolactin. Several 5-HT agonists were administered, in a dose-response fashion, to conscious rats and the effect on the levels of prolactin in plasma was measured. The 5-HT1A + 5-HT1B agonist RU 24969 (5-methoxy-3[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole succinate) and the 5-HT1 + 5-HT2 agonist MK-212 (6-chloro-2-[1-piperazinyl]pirazine) increased levels of prolactin in plasma in a dose-dependent manner. In contrast, the selective 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) and ipsapirone (2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3 -(2H) one-1,1-dioxidehydrochloride) did not increase levels of prolactin in plasma at any dose. The 5-HT-releasing drug, fenfluramine, also increased the concentration of prolactin in plasma. Pretreatment with the selective 5-HT2 antagonist, LY53857 (6-methyl-1-[1-methylethyl]ergoline-8-carboxylic acid, 2-hydroxy-1-methyl propyl ester (Z)-2-butenedioate [1:1]), did not significantly diminish an increase in levels of prolactin in plasma, induced by injection of fenfluramine. The antagonist LY53857 inhibited, but did not block the MK-212- and RU 24969-induced increase in the levels of prolactin in plasma. By deduction, these data suggest that 5-HT1B receptors, or as yet undefined 5-HT receptor subtypes may be involved in the stimulation of the secretion of prolactin by endogenously released 5-HT, and that 5-HT2 receptors may play a minor role in the serotonergic regulation of the secretion of prolactin.

A comparison of acute stress paradigms: Hormonal responses and hypothalamic serotonin

The effects of stress on plasma renin activity (PRA), plasma prolactin and corticosterone levels, and hypothalamic 5-HT and 5-HIAA concentrations were investigated using a 3 and 12 min conditioned fear (CER) paradigm; 20 min immobilization; 20 min exposure to shallow or deep cold water; 2, 12 and 22 min of intermittent footshock with or without 20 min recovery; and, a 3 min CER with 0, 10, 30 and 60 min recovery. PRA was increased by all the stressors, except shallow cold water, reaching a maximum after 12 min and returning to control values within 10-20 min post-stress. Prolactin levels also were increased by all the stressors, except shallow and deep cold water. Prolactin levels were maximal after 12 min and returned to baseline within 20-60 min post-stress, depending on the stressor. Corticosterone levels were elevated by all the stressors, but not as rapidly as PRA or prolactin, reaching a maximum after about 20 min and returning to baseline concentrations within 30-60 min post-stress. None of the stressors produced significant changes in hypothalamic 5-HT and 5-HIAA concentrations.

Fluoxetine gradually increases [125I]DOI-labelled 5-HT2A/2C receptors in the hypothalamus without changing the levels of Gq- and G11-proteins

The time course of fluoxetine-induced supersensitivity of hypothalamic 5-HT2A/2C receptors was examined. Daily injections of fluoxetine (7 or 14 days) significantly increased agonist ([125I]DOI)-labeled high-affinity-state 5-HT2A/2C receptors in the hypothalamus, but not frontal cortex. No change was observed in the density of [3H]ketanscrin-labeled 5-HT2A receptors in either brain region. The levels of Gq- and G11- proteins in the hypothalamus and cortex were not altered by fluoxetine. These results suggest that fluoxetine gradually increases the G-protein coupling of 5-HT2A/2C receptors without altering the levels of Gq- or G11-proteins.

Effect of Selective Midbrain and Diencephalic 5,7-Dihydroxytryptamine Lesions on Serotonin Content in Individual Preopticohypothalamic Nuclei and on Serum Luteinizing Hormone Level

Injection of the serotonin neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT), into the midbrain dorsal (DR) or median (MR) raphe nucleus of castrated and normal male rats was followed by measurement of serum luteinizing hormone (LH) level and the 5-hydroxytryptamine (5-HT) content of several hypothalamic and amygdaloid nuclei. Only the DR lesions lead to a significant decrease (42%) in serum LH level in normal rats. The elevated LH level in castrated animals was not affected by either lesion. The DR lesions were followed by 5-HT reductions only in the medial preoptic area, the arcuate and ventromedial hypothalamic nuclei, and in the basal and central amygdaloid nuclei. In contrast, the 5-HT reductions produced by MR lesions were much more widespread, being found in all nuclei assayed with the exception of the dorso- and ventromedial hypothalamic nuclei. In a second experiment, degeneration of serotonergic terminals in the ventromedial region of the hypothalamus following intradiencephalic injections of 5,7-DHT led to a significant decrease in serum LH level and a 5-HT reduction in the arcuate, ventromedial and dorsomedial hypothalamic nuclei. 5,7-DHT injections into the medial preoptic area and the anterior hypothalamic area did not affect serum LH level. These results suggest that a serotonergic pathway originating in the midbrain dorsal raphe nucleus and innervating the mediobasal hypothalamus has a stimulatory influence on LH secretion.

Estrogen treatment increases the levels of regulator of G protein signaling-Z1 in the hypothalamic paraventricular nucleus: possible role in desensitization of 5-hydroxytryptamine1A receptors

Desensitization of post-synaptic serotonin1A (5-HT1A) receptors may underlie the clinical improvement of neuropsychiatric disorders. In the hypothalamic paraventricular nucleus, Galphaz proteins mediate the 5-HT1A receptor-stimulated increases in hormone release. Regulator of G protein signaling-Z1 (RGSZ1) is a GTPase-activating protein selective for Galphaz proteins. RGSZ1 regulates the duration of interaction between Galphaz proteins and effector systems. The present investigation determined the levels of RGSZ1 in the hypothalamic paraventricular nucleus of rats subjected to four different treatment protocols that produce desensitization of 5-HT1A receptors. These protocols include: daily administration of beta estradiol 3-benzoate (estradiol) for 2 days; daily administration of fluoxetine for 3 and 14 days; daily administration of cocaine for 7 or 14 days; and acute administration of (+/-)-1-(2,5 dimethoxy-4-iodophenyl)-2-amino-propane HCl (DOI; a 5-HT2A/2C receptor agonist). Estradiol treatment was the only protocol that increased the levels of RGSZ1 protein in the hypothalamic paraventricular nucleus in a dose-dependent manner (46%-132% over control). Interestingly, previous experiments indicate that only estradiol produces a decreased Emax of 5-HT1A receptor-stimulation of hormone release, whereas fluoxetine, cocaine and DOI produce a shift to the right (increased ED50). Thus, the desensitization of 5-HT1A receptors by estradiol might be attributable to increased levels of RGSZ1 protein. These findings may provide insight into the adaptation of 5-HT1A receptor signaling during pharmacotherapies of mood disorders in women and the well-established gender differences in the vulnerability to depression.

Repeated cocaine exposure inhibits the adrenocorticotropic hormone response to the serotonin releaser d-fenfluramine and the 5-HT1A agonist, 8-OH-DPAT

The influence of cocaine exposure on serotonergic neurons and postsynaptic 5-HT1A receptor-mediated responses was evaluated by measuring neuroendocrine responses to a serotonin (5-HT) releaser or a 5-HT1A agonist. Male rats received cocaine (15 mg/kg, i.p.) or saline twice daily for 7 days. Forty-two hr after the final cocaine injection, the 5-HT releaser d-fenfluramine (0, 0.2, 0.6, 2, or 5 mg/kg, i.p.) or the 5-HT1A agonist, 8-OH-DPAT (0, 10, 50, 200 or 500 micrograms/kg, s.c.) were administered. Blood samples were then collected for analysis of plasma ACTH, prolactin, and renin concentrations. The ACTH responses to d-fenfluramine and 8-OH-DPAT were inhibited in cocaine pretreated rats. However, the prolactin responses to d-fenfluramine and 8-OH-DPAT were not significantly modified by cocaine exposure. Additionally, the renin response to d-fenfluramine was unaltered by repeated cocaine administration, while 8-OH-DPAT did not alter renin secretion in either pretreatment group. In contrast to published reports which show that cocaine exposure produces supersensitive 5-HT2A and/or 5-HT2C receptor-mediated responses, the present data suggest that repeated cocaine exposure produces subsensitivity to at least some postsynaptic 5-HT1A receptors. Cocaine-induced deficits in the ACTH response to 5-HT releasers may reflect 5-HT1A receptor subsensitivity, but presynaptic deficits cannot be excluded. Examination of the ACTH response to 5-HT1A agonists may represent a valuable approach to determine deficits in 5-HT function in human cocaine abusers.

Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT1A receptors with no change in 5-HT2A receptors

Although women constitute the majority of patients who receive treatment with selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, most animal studies of SSRIs are conducted on males. The present study investigated whether long-term treatment of cycling female rats with fluoxetine alters their estrous cycle and the sensitivity of hypothalamic serotonin (5-HT) 5-HT(1A) and 5-HT(2A) receptor systems. Adult female rats received daily injections of fluoxetine (10 mg/kg, i.p.) for three consecutive estrous cycles (15.2+/-0.2 days) with the first injection beginning on metestrus (when circulating estrogen levels are low and stable). Fluoxetine did not alter basal plasma estradiol levels at metestrus, nor did it alter the pattern of estrous cyclicity. Rats treated with fluoxetine showed a loss in body weight. On the morning of metestrus of the fourth cycle (18 h after the last fluoxetine injection), the rats were injected with a sub-maximal dose of the 5-HT(1A) agonist (+/-)-8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT, 50 MICRO/kg, s.c.) or a maximal dose of the 5-HT(2A) agonist [(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl] (DOI). Plasma levels of oxytocin, ACTH and corticosterone were measured as peripheral indicators of hypothalamic 5-HT(1A) and 5-HT(2A) receptor sensitivity. Injecting 8-OH-DPAT to saline pretreated rats produced a significant increase in plasma oxytocin (299%), ACTH (1456%) and corticosterone (170%) levels but not in plasma prolactin or renin concentrations. Greater increases in plasma levels of these hormones were observed after injecting DOI. Fluoxetine treatment completely blocked the oxytocin, ACTH and corticosterone responses to 8-OH-DPAT, but did not inhibit the effect of DOI on any hormone, thus confirming that fluoxetine treatment did not produce a deficit in the functioning of corticotropin releasing hormone or oxytocin containing neurons. These results indicate that in cycling female rats, fluoxetine treatment desensitizes hypothalamic post-synaptic 5-HT(1A) receptor signaling. Understanding the pharmacological effects of fluoxetine in females may lead to more effective treatment of women with mood disorders.

Prior chronic exposure to cocaine inhibits the serotonergic stimulation of ACTH and secretion of corticosterone

The effect of long-term pretreatment with cocaine on serotonergic regulation of ACTH (adrenocorticotropic hormone; corticotropin) and secretion of corticosterone in rats was investigated. The following observations were made: (1) Pretreatment with cocaine had no significant effect on basal levels of ACTH and corticosterone in plasma. However, cocaine caused a reduction in the ability of the 5-HT (5-hydroxytryptamine, serotonin) releaser p-chloroamphetamine (PCA) to increase corticosterone in plasma, 42 hr after the last injection of cocaine. (2) Exposure to cocaine for 7 days was sufficient to produce a maximal inhibition of the PCA-induced increase in ACTH in plasma. (3) The inhibitory effect of cocaine on PCA-induced release of ACTH was more marked than on corticosterone. (4) Conversely, the dose-dependent stimulatory effect of two 5-HT1 agonists, RU 24969 (5-methoxy-3-(1,2,3,4-tetrahydro-4-pyridinyl)-1H-indole) and m-CPP (m-chlorophenylpiperazine), on ACTH and corticosterone was not reduced by 7 days of exposure to cocaine. Taken together, these findings indicate that pretreatment with cocaine reduced the function of serotonergic nerve-terminals but not postsynaptic receptors, that stimulate ACTH and secretion of corticosterone.